Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Holland Bloorview Kids Rehabilitation Hospital
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rare
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluoxetine (this asset) | Holland Bloorview Kids Rehabilitation Hospital | N/A | D · 30 |
| Burosumab | Bicetre Hospital | P4 | BB |
| Irinotecan | Gradalis, Inc. | P3 | B |
| Crofelemer | Napo Pharmaceuticals, Inc. | P2/3 | B |
| Nivestim | Hospices Civils de Lyon | P2/3 | B |
| Gemogenovatucel-T | Gradalis, Inc. | P3 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Prisma Health-Upstate | P2 | CCC |
| Durvalumab | Prisma Health-Upstate | P2 | CCC |
| Anti-Her2 Antibody-Drug Conjugate A166 | Klus Pharma Inc. | P1/2 | CCC |
+3 more in the Rare cohort
Other indications for Fluoxetine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Depressive Disorder | — | P4 | BBB · 74 |
| Anxiety Disorder | — | P4 | BBB · 74 |
| Mood Disorder | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluoxetine in Rare. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluoxetine-rare
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →